TrialClinical ophthalmology (Auckland, N.Z.)2026
Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension for Dry Eye Disease: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Trial.
Yuichi Hori et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.